Does ENZALUTAMIDE Cause Mobility decreased? 187 Reports in FDA Database
Prostate Health & Male Vitality — Naturally
ProstaVive: better flow, better sleep, better energy. 180-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 187 reports of Mobility decreased have been filed in association with ENZALUTAMIDE (Xtandi). This represents 0.4% of all adverse event reports for ENZALUTAMIDE.
187
Reports of Mobility decreased with ENZALUTAMIDE
0.4%
of all ENZALUTAMIDE reports
36
Deaths
64
Hospitalizations
How Dangerous Is Mobility decreased From ENZALUTAMIDE?
Of the 187 reports, 36 (19.3%) resulted in death, 64 (34.2%) required hospitalization, and 2 (1.1%) were considered life-threatening.
Is Mobility decreased Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for ENZALUTAMIDE. However, 187 reports have been filed with the FAERS database.
What Other Side Effects Does ENZALUTAMIDE Cause?
Fatigue (8,891)
Death (6,680)
Malignant neoplasm progression (4,696)
Prostatic specific antigen increased (3,731)
Asthenia (3,589)
Drug ineffective (3,468)
Hot flush (3,144)
Decreased appetite (3,069)
Nausea (2,898)
Dizziness (2,776)
What Other Drugs Cause Mobility decreased?
ADALIMUMAB (8,829)
ETANERCEPT (8,321)
METHOTREXATE (5,936)
ABATACEPT (4,519)
TOCILIZUMAB (4,403)
LEFLUNOMIDE (4,354)
HYDROXYCHLOROQUINE (4,105)
RITUXIMAB (4,067)
INFLIXIMAB (3,784)
TOFACITINIB (3,734)
Which ENZALUTAMIDE Alternatives Have Lower Mobility decreased Risk?
ENZALUTAMIDE vs EPCORITAMAB
ENZALUTAMIDE vs EPCORITAMAB-BYSP
ENZALUTAMIDE vs EPERISONE
ENZALUTAMIDE vs EPHEDRINE
ENZALUTAMIDE vs EPINASTINE